Latest Whitepapers

Download this whitepaper to discover how third generation sequencing can identify disease-causing variants with complex genetic etiology, detect SARS-CoV-2 and provide novel genetic insights.

Assays, such as the enzyme-linked immunosorbent assay (ELISA), are being developed to detect the presence of anti-SARS-CoV-2 antibodies in patient sera. Download this article to discover an ELISA that is more sensitive than a lateral flow immunoassay.

Many regulatory guidelines state that cell banks and cultures used in the production of biologics must be tested for mycoplasma. Mycoplasma infections can cause severe problems in manufacturing as these organisms can alter DNA, RNA and modify host cell plasma membrane antigens.

Bioconjugation is the chemical linking of two biomolecules to form a single hybrid that retains the biological activity of each component, yet provides a novel function that is not possible with each individual biomolecule.

Download this whitepaper to discover how LC-MS can deliver unmatched analyte specificity for antibody-drug conjugates with high-throughput analyses and is useful in product development.

Proteins are one of the most vital parts of living organisms with many functions, using the latest proteomics methods it is now possible to understand how protein changes in our body influence health and disease, particularly during ageing.

Vaccination is largely recognized as the most cost-effective way to fight human infectious diseases. Vaccines play a vital role in immunization strategies that have helped to eradicate dangerous pathogens, increase human life expectancy and reduce disabilities and suffering all around the world.

It is paramount within the pharmaceutical industry that scientists can manage large amounts of data efficiently and safely. The Cubis® II balance series was designed for customizable modularity, meeting the needs of the industry whilst maintaining full compliance.

Single-cell sequencing is quickly becoming a standard tool in biological research due to the scale and depth of insight it provides across diverse cell populations. The pharmaceutical industry is exploiting single-cell approaches to identify novel therapeutic targets and accelerate promising assets through development.

The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.